Medical Mutual coverage for Zepbound (Weight Loss)

Employer / Commercial Insurance

Depends on your plan's benefit

Prior Authorization is only available for members with plan benefit coverage of weight loss drugs. Medications for the treatment of weight loss are specifically excluded as a covered benefit for many plans.

What you need to qualify

Age 18 and older
BMI of 32 or higher
BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, OSA, CVD, knee osteoarthritis, asthma, COPD, NASH/NAFLD, PCOS, and CAD)
3 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Adult Initial Therapy (age >= 18)

All of:

Patient is >= 18 years of age
Patient has engaged in a trial of behavioral modification and dietary restriction for at least 3 months
Zepbound will be used concomitantly with a behavioral modification program and a reduced-calorie diet
Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology

Plus any one of:

At baseline, patient had a BMI >= 32 kg/m2
At baseline, patient had a BMI >= 27 kg/m2 AND at least TWO of the following weight-related comorbidities: hypertension, type 2 diabetes, dyslipidemia, OSA, CVD, knee osteoarthritis, asthma, COPD, NASH/NAFLD, PCOS, or CAD

Adult Continuation Therapy (age >= 18)

All of:

Patient is >= 18 years of age
Patient has lost >= 5% of baseline body weight
Zepbound will be used concomitantly with a behavioral modification program and a reduced-calorie diet
Prescriber does not specialize primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology
Patient has completed at least 8 months of initial therapy OR is within initial approval period

Plus any one of:

At baseline, patient had a BMI >= 32 kg/m2
At baseline, patient had a BMI >= 27 kg/m2 AND at least TWO weight-related comorbidities

Documentation to bring

Documentation of baseline BMI (>= 32 kg/m2, OR >= 27 kg/m2 with at least two qualifying comorbidities) prior to any GLP-1 or GLP-1/GIP agonist use
Documentation of at least 3-month trial of behavioral modification and dietary restriction
For BMI >= 27 pathway: documentation of at least two qualifying weight-related comorbidities
For continuation: documentation of >= 5% baseline body weight loss
For continuation: prescriber attestation of ability to tolerate maintenance dose (5 mg, 10 mg, or 15 mg once weekly) or confirmation of ongoing dose titration toward 10 mg or 15 mg once weekly
Prescriber specialty credentials (to confirm not in excluded specialty)

Approval and renewal

Initial approval: 8 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight, Adult: must have lost >= 5% of baseline body weight. Patient must be able to tolerate a Zepbound maintenance dose of 5 mg, 10 mg, or 15 mg once weekly for 1-year approval; if still titrating to 10 mg or 15 mg and < 12 consecutive months received, approve for up to 4 months. Baseline BMI eligibility is re-verified at continuation, and staying on a maintenance dose of at least 5 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Concomitant use with other FDA-approved weight loss medications (e.g., phentermine, benzphetamine, diethylpropion, phendimetrazine, Contrave, Qsymia, orlistat)
Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists
Prescriber who specializes primarily in: anesthesiology, dentistry, emergency medicine, nuclear medicine, ophthalmology, pathology, or radiology

Policy note: Zepbound weight loss indication applies to adults only (no pediatric criteria listed for Zepbound weight loss in this policy). Initial approval is 8 months. Continuation is 1 year if maintenance dose (5, 10, or 15 mg once weekly) is tolerated; up to 4 months if still titrating to 10 or 15 mg and <12 consecutive months completed. The policy notes that 5 mg once weekly should be achievable within the 8-month initial period. Baseline BMI refers to baseline prior to any GLP-1 or GLP-1/GIP agonist use.

verified June 10, 2026 · source: Weight-Loss-GlucagonLike-Peptide1-GLP1-Agonists.pdf